Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s stock price dropped 23.5% during trading on Saturday . The company traded as low as C$0.09 and last traded at C$0.13. Approximately 119,000 shares changed hands during trading, an increase of 588% from the average daily volume of 17,288 shares. The stock had previously closed at C$0.17.
Devonian Health Group Stock Down 23.5%
The company has a 50-day moving average price of C$0.16 and a 200 day moving average price of C$0.17. The company has a debt-to-equity ratio of 16.36, a current ratio of 1.07 and a quick ratio of 7.82. The firm has a market capitalization of C$19.27 million, a PE ratio of -4.64 and a beta of 0.67.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
Featured Stories
- Five stocks we like better than Devonian Health Group
- How to Use Stock Screeners to Find Stocks
- Tesla: 2 Reasons to Love Musk’s $1B Buy, 1 Reason to Be Bearish
- Want to Profit on the Downtrend? Downtrends, Explained.
- Azure Leads While AI Excitement Fuels Microsoft Stock
- What is Insider Trading? What You Can Learn from Insider Trading
- Darden Restaurants: A Textbook Buy-the-Dip Opportunity
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
